<DOC>
	<DOC>NCT01777932</DOC>
	<brief_summary>This multicenter, single-arm observational study will evaluate the clinical benefits of Avastin (bevacizumab) in combination with paclitaxel in first-line treatment in patients with metastatic breast cancer. Patients with metastatic breast cancer who have started Avastin treatment within 6 months prior to study start will also be eligible. Data will be collected from patients for up to 5 years.</brief_summary>
	<brief_title>AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients with metastatic breast cancer initiated on firstline treatment with Avastin in combination with paclitaxel according to the current Hungarian summary of Product Characteristics Patients with metastatic breast cancer initiated within 6 months before the start of the study on treatment with Avastin according to the current Hungarian Summary of Product Characteristics Contraindications for Avastin according to the current Hungarian Summary of Product Characteristics: Hypersensitivity to active ingredient of Avastin or to any excipients Hypersensitivity to products produced in Chinese hamster cells or to other recombinant or humanized antibodies Pregnancy Untreated central nervous system metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>